Different Mutant/Wild-Type p53 Combinations Cause a Spectrum of Increased Invasive Potential in Nonmalignant Immortalized Human Mammary Epithelial Cells  by Junk, Damian J. et al.
Different Mutant/Wild-Type p53
Combinations Cause a Spectrum
of Increased Invasive Potential in
Nonmalignant Immortalized
Human Mammary Epithelial Cells1
Damian J. Junk*,†, Lukas Vrba†, George S. Watts†,‡,
Marc M. Oshiro†, Jesse D. Martinez*,†,§
and Bernard W. Futscher*,†,¶
*Cancer Biology Graduate Interdisciplinary Program, The
University of Arizona, Tucson, AZ 85724, USA; †Arizona
Cancer Center, The University of Arizona, Tucson, AZ 85724,
USA; ‡Department of Pharmacology, College of Medicine,
The University of Arizona, Tucson, AZ 85724, USA;
§Department of Cell Biology and Anatomy, The University
of Arizona, Tucson, AZ 85724, USA; ¶Department of
Pharmacology & Toxicology, College of Pharmacy, The
University of Arizona, Tucson, AZ 85724, USA
Abstract
Aberrations of p53 occur in most, if not all, human cancers. In breast cancer, p53 mutation is the most common
genetic defect related to a single gene. Immortalized human mammary epithelial cells resemble the earliest forms
of aberrant breast tissue growth but do not express many malignancy-associated phenotypes. We created a model
of human mammary epithelial tumorigenesis by infecting hTERT-HME1 immortalized human mammary epithelial
cells expressing wild-type p53 with four different mutant p53 constructs to determine the role of p53 mutation on
the evolution of tumor phenotypes. We demonstrate that different mutant/wild-type p53 heterozygous models
generate loss of function, dominant negative activity, and a spectrum of gain of function activities that induce
varying degrees of invasive potential. We suggest that this model can be used to elucidate changes that occur
in early stages of human mammary epithelial tumorigenesis. These changes may constitute novel biomarkers or
reveal novel treatment modalities that could inhibit progression from primary to metastatic breast disease.
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Introduction
Inactivation of the tumor suppressor gene p53 occurs in most human
cancers [1]. In breast cancer, loss of one p53 allele occurs in 47% to
64% of tumor tissues with no evidence of homozygous deletion and
no significant correlation with mutation of the remaining allele [2–5].
Mutation of the p53 gene occurs in 15% to 30% of breast cancers,
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making this the most common genetic defect related to a single gene
[6–9]. Mutation of p53 causes accumulation of the protein that can be
detected in tissue by immunohistochemistry [4]. Because the mutant
p53 protein is retained and accumulated, it has been hypothesized that
it plays a functional role in tumorigenesis.
The role of p53 mutation has often been analyzed in malignantly
transformed cancer cell lines that are p53 wild-type or p53 null. These
studies have shown that DNA binding domain mutations of p53 pro-
duce three possible consequences: loss of wild-type p53 function, dom-
inant negative activity, and gain of function. Mutant p53 was shown to
bind DNA less efficiently than wild-type p53, demonstrating a loss of
function phenotype [10,11]. Coinfection studies of wild-type and mu-
tant p53 in a p53 null background showed reduced expression of wild-
type p53 target genes, which was linked to a concomitant decrease in
DNA binding demonstrating a dominant negative activity [12]. Gain
of function for mutant p53 was demonstrated in p53 null cancer cell
lines through increased growth in soft agar and tumorigenicity in
mouse xenografts, which were likely due in part to changes in gene ex-
pression caused by the mutant p53 protein [13–19].
Two recent studies have examined the effect of p53 mutant/wild-
type heterozygosity on tumor development in mice [20,21]. Knock-in
of two mutant p53 alleles, R172H or R270H, in a wild-type p53 back-
ground demonstrated specific accumulation of p53 in tumor tissues
that did not occur in surrounding normal tissue. Loss of the remaining
wild-type p53 allele did occur but was not universal among all tumor
types. Although the mutant p53 knock-in mice displayed similar tu-
mor development and organism survival rates to p53 heterozygous
knockout mice, there was an increase in osteosarcomas, premalignant
epithelial lesions, and carcinomas in response to the mutant p53.
Finally, the osteosarcomas and epithelial tumors of these mice were
locally invasive or frequently metastasized compared to the p53 hetero-
zygous knockout mice, which completely lacked metastases. Thus,
mutant p53 specifically accumulated in tumor tissues, and accumula-
tion was associated with the development of a metastatic phenotype
often, despite the presence of a functional wild-type p53 allele.
In the present study, we extend these findings to human mammary
epithelial cells (HMEC) by the introduction of four mutant p53 pro-
teins (R175H, R273H, R280K, and R249S) into wild-type p53,
hTERT-immortalized HMEC, hTERT-HME1 (HME1), using a
lentiviral delivery system. Human mammary epithelial cell culture
and immortalization has been studied extensively [22–24]. Ectopic
expression of the hTERT gene can rapidly convert postselection
HMEC to full immortalization [25]. Recent studies of the contin-
uum of HMEC cultures suggest that immortalized HMEC do re-
semble some of the earliest forms of aberrant breast tissue growth,
but they do not display malignant phenotypes [26]. Culture models
suggest that addition of oncogenes such as ZNF217 and activated
RAS confer many of the malignancy-associated phenotypes missing
in immortalized HMEC [27,28]. Similarly, we used this cell culture
model to analyze the effect of mutant/wild-type p53 heterozygosity
on malignant phenotypes.
We show that accumulation of exogenous mutant p53 is accom-
panied by an equivalent increase in wild-type p53 in the HME1 cells.
We demonstrate that dominant negative activity of mutant p53 is
sufficient to inhibit wild-type p53 binding to DNA and to alter pat-
terns of wild-type p53 target gene expression. Furthermore, we show
that accumulation of each mutant p53 results in unique changes in
gene expression and a spectrum of increased invasive potential of
these cells. The results of our model system agree with previously
described functional consequences of p53 mutation and extend the
increased invasiveness and metastatic potential of p53 mutant/wild-
type heterozygous status to human mammary epithelial cells. This
model will be useful for determining how p53 mutation drives the
progression of a noninvasive primary tumor to metastatic breast can-
cer in humans.
Materials and Methods
Cell Culture and Doxorubicin Treatment
The cell lines hTERT-HME1, MDA-MB-468, MDA-MB-231,
and BT549 were purchased from the American Type Culture Collec-
tion (Rockville, MD). 293FT cells were purchased from Invitrogen
(Carlsbad, CA). The hTERT-HME1 cells were grown in mammary
epithelial cell growth medium (Cell Applications, San Diego, CA).
293FT cells were grown according to Invitrogen’s protocols. The
others were cultured as previously described [29]. Doxorubicin (Sigma-
Aldrich, St. Louis, MO) was added for 18 hours to the cell culture media
at a final concentration of 500 nM.
Adenoviral Infections
Adenovirus containing wild-type p53 with GFP, R175H mutant
p53 with GFP, or with GFP alone was the kind gift of Bert Vogelstein
and was propagated as previously described [29]. Adenovirus was
added to the growth media at 100 plaque-forming units per cell
for 24 hours.
Nucleic Acid Isolation
Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Va-
lencia, CA). Genomic DNA was isolated using a DNeasy Blood and
Tissue Kit (Qiagen).
Mutant p53 Cloning
Four mutant p53 sequences were isolated from MDA-MB-231
(R280K), MDA-MB-468 (R273H), BT549 (R249S) or the R175H
adenovirus. Extensive genomic sequencing analysis of MDA-MB-231
cells conducted by our laboratory show they express only mutant p53
R280K. According to the International Agency for Research on Cancer
mutant p53 database, the MDA-MB-468 cells lost the wild-type allele
and expressed only mutant p53 R273H. BT549 harbors the mutant
p53 R249S, and the status of the other allele is unknown. The p53 se-
quences were reverse-transcribed using a gene-specific primer and the
Superscript III kit (Invitrogen). Blunt-ended polymerase chain reaction
(PCR) fragments of the p53 constructs were generated by the Plati-
num Pfx DNA polymerase kit (Invitrogen). Primer sequences are avail-
able on request.
Lentiviral Particle and Stable Cell Line Generation
The four mutant p53 PCR products were cloned into the pLenti6/
V5-D-Topo vector (Invitrogen). Each construct was validated for the
correct p53 mutation by DNA sequencing. Lentiviral particles were
generated by individually transfecting 293FT cells with the four mu-
tant p53 pLenti6/V5 constructs and the ViraPower Packaging Mix
with Lipofectamine 2000 according to the manufacturer’s protocol
(Invitrogen). Stable mutant p53–expressing HME1 cells were gen-
erated by infection with lentiviral particles at a 1:100 dilution in
growth media with 6 μg/ml polybrene (Sigma-Aldrich). Selection
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of stably expressing mutant p53 cell lines was conducted with 2 μg/ml
blasticidin (Invitrogen).
Immunoprecipitation and Western Blot Analyses
Protein was isolated in radio immunoprecipitation assay buffer and
was quantitated by the Bio-Rad Protein Assay (Bio-Rad Laboratories,
Hercules, CA). Total protein (1 mg) was precleared. A total of 2 μg of
α-V5 (Invitrogen) or IgG2a isotype control antibody (Calbiochem,
San Diego, CA) was added and rotated overnight at 4°C. Protein A/G
beads (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) were added
to each sample for 1 hour, and beads were washed four times in radio
immunoprecipitation assay buffer and twice in phosphate-buffered
saline (PBS). Immunoprecipitates or 30 μg of total protein lysates
was loaded into 7.5% Tris–HCl Ready Gels (Bio-Rad Laboratories),
except the V5 Western blot in Figure 1, which was loaded into 10%
Tris–HCl Ready Gels (Bio-Rad Laboratories). Blots were incubated
with either α-V5 HRP-conjugated antibody (Invitrogen) or α-p53
HRP-conjugated antibody clone DO-1 (Santa Cruz Biotechnology,
Inc.) and α-actin clone AC40 (Sigma-Aldrich). For actin, a goat
anti–mouse HRP secondary antibody (Santa Cruz Biotechnology,
Inc.) was used for detection. Blots were incubated with ECLWestern
Blotting Detection Reagents (Amersham Biosciences, Piscataway,
NJ) and were exposed to BioMax XAR film (Kodak, Rochester,
NY). Western blots from three independent immunoprecipitations
were captured and quantitated using the Gel Logic 200 Imaging Sys-
tem and associated software (1D v3.6.4; Kodak).
Subcellular Localization of p53
Cells grown on coverslips were fixed with 4% paraformaldehyde in
PBS, permeabilized with 0.2% Triton X-100, and blocked with 5%
BSA. Fixed cells were incubated for 1 hour with α-p53 primary anti-
body AB-6 clone DO-1 (Calbiochem). Cells were then stained for
1 hour with anti–mouse IgG Cy3 secondary antibody (Sigma-Aldrich).
Nuclei were visualized with 4′,6-diamidino-2-phenylindole (Molecular
Probes, Inc., Eugene, OR). Coverslips were mounted on glass slides,
and stained cells were analyzed using fluorescent microscopy.
Real-Time Reverse Transcription–Polymerase Chain Reaction
Real-time reverse transcription–polymerase chain reaction (RT-PCR)
was conducted forWIG1, p21,MDM2, and GAPDH according to the
Applied Biosystems (Foster City, CA) protocol as previously described
[29]. For TP53I3, STAU-2, E2F5, CDH11, TFPI2, and β-actin,
primers were designed for use with the Human Universal Probe
Library Set (Roche Diagnostics, Indianapolis, IN) and conducted
on an ABI Prism 7000 Sequence Detection System (Applied Bio-
systems) with a 95°C denaturation for 3 minutes followed by 40 cy-
cles of 95°C for 15 seconds and 60°C for 45 seconds. All experiments
were conducted in triplicate from three independent RNA isolations.
Primer sequences are available on request.
13k Human Promoter Microarray
Primers were obtained from the Whitehead Institute [30]. Micro-
array probes were generated from a pooled sample of human mono-
nuclear genomic DNA by PCR (ABgene, Rochester, NY). Products
were analyzed by the E-Gel 96 system (Invitrogen), purified using
the QIAquick 96 PCR Purification Kit (Qiagen), and quantified
using the ND-1000 spectrophotometer (Nanodrop Technologies,
Wilmington, DE). DNA was lyophilized and resuspended in 10 μl
of 3× SSC for printing onto Ultra GAPS slides (Corning, Lowell,
MA) using an OmniGrid robot (GeneMachines, San Carlos, CA).
Slides were hydrated and UV cross-linked. Slides were preincubated
with 1% BSA, 4× SSC, 0.5% SDS at 42°C, followed by incubation
in 1% SDS, 0.25% sodium borohydride at 42°C. Slides were washed
in 0.06× SSC, 0.1% SDS, then in 0.06× SSC, and then in double-
distilled water.
Microarray Detection of p53 Binding
p53-Specific chromatin immunoprecipitation (ChIP) was per-
formed using antibody clone DO-1 (AB-6; Calbiochem) as previ-
ously described, except that the final purification was done using a
QIAquick PCR purification kit (Qiagen) [31]. Immunoprecipitated
DNA was quantified using PicoGreen dye (Invitrogen). Equal
amounts of ChIP and input DNA were amplified using the BioPrime
DNA Labeling System (Invitrogen). Second-round amplification was
conducted with Cy3 and Cy5 dyes for labeling (GE healthcare, Pis-
cataway, NJ). Labeled DNA was purified using a QIAquick PCR pu-
rification kit (Qiagen). Labeled targets were mixed with 20 μg of
human Cot-1 DNA (Invitrogen) and 40 μg of yeast tRNA (Invitro-
gen), dried under vacuum, dissolved in Domino Oligo Hybridization
Buffer DMH-25 (Gel Company, San Francisco, CA), and denatured.
Samples were hybridized to processed slides in an ArrayBooster (Ad-
valytix AG, Concord, MA) at 42°C for 16 hours. Hybridized slides
were washed in 2× SSC, 0.1% SDS, then 0.06× SSC, 0.1% SDS,
and finally 0.06× SSC. Slides were scanned using an Axon GenePix
4000 (Axon Instruments, Inc., Foster City, CA). Experiments were
done in triplicate using dye swap resulting in six slides per cell line.
The data were analyzed using limma package for R [32]. Arrays were
normalized using loess function for within array normalization and
quantile function for between array normalization. A linear model fit
was calculated using input as a common reference. The elements re-
ferred to as bound by p53 within this paper were enriched in cell
treatments over parental at P value ≤ .01.
Real-Time PCR Verification of ChIP-Chip Analysis
p53-Specific ChIP was performed as described for the microarray in
previous paragraphs. Immunoprecipitated DNA was quantified using
PicoGreen dye (Invitrogen) and a BioTek FLx800 Multi-Detection
Microplate Reader (BioTek Instruments, Winooski, VT). Equal
amounts (100 pg) of ChIP and input DNA were used for real-time
PCR analysis. Enrichment was calculated as previously described
[31]. Primer sequences are available on request. Mutant p53 inhibited
binding to an extent that very little DNA was yielded compared to the
wild-type p53 infection. The yield from the mutant p53 cell lines was
so miniscule it was not possible to assay them with this real-time
PCR method.
Microarray Expression Analysis
Total RNA was processed according to the protocol recommended
by Affymetrix (Santa Clara, CA). In all, 20 μg of labeled cRNA from
each sample was hybridized to the GeneChip Human Genome
U133A Plus 2.0 Array (Affymetrix). The expression data were ana-
lyzed using GeneSpring GX 7.3.1 (Agilent Technologies, Santa
Clara, CA). Data were normalized per chip to the 50th percentile
then to the hTERT-HME1 reference cell lines (HME1 parental, vec-
tor only lentivirally infected, and GFP adenovirally infected). Gene
lists were generated using a two-fold cutoff for both of two replicates
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of each p53 treatment studied compared to the GFP cell lines for
wild-type p53 and vector only for mutant p53.
Flow Cytometry
Parental HME1, vector only control, mutant p53–expressing cell
lines, adenoviral GFP, and wild-type p53–infected cells were analyzed
in duplicate by flow cytometry. For serum deprivation experiments,
parental HME1, vector only control, and mutant p53–expressing cell
lines were exposed to basal growth media for 24 hours then subjected
to flow cytometry analysis in duplicate. Cells were harvested, washed,
and incubated overnight with 95% ethanol. Cells were pelleted and
resuspended in PBS, treated with RNase A, and stained with propi-
dium iodide (Sigma-Aldrich). Flow cytometric analysis was per-
formed using a FACScan flow cytometer (BD Biosciences, San
Jose, CA) equipped with an air-cooled 15-mW argon ion laser tuned
to 488 nm. List mode data files consisting of 10,000 events gated on
forward scatter versus side scatter were acquired and analyzed using
CellQuest PRO software (BD Biosciences) at a rate of 200 to 400
events per second. Curve fit analysis was prepared using ModFit
LT version 3.1 (BD Biosciences).
Cell Proliferation Assay
HME1, vector only, and mutant p53–expressing cells were
counted on a Vi-CELL (Beckman Coulter, Inc., Fullerton, CA),
and 60,000 cells were plated in T-25 flasks in triplicate at day 0. Cells
were counted on a Vi-CELL (Beckman Coulter, Inc.) at days 1, 3,
and 5 in triplicate.
Clonogenic Assay
HME1, vector only, and mutant p53–expressing cells were counted
on a Vi-CELL (Beckman Coulter, Inc.) and were plated in triplicate at
125, 63, and 31 cells/well dilutions. The cells were grown for 2 weeks
and were stained with 500 μl of 0.5% crystal violet in 20% methanol.
Colonies were counted manually in triplicate.
Anchorage-Independent Growth
HME1, vector only, mutant p53–expressing cells, and MDA-MB-
231 cells were counted on a Vi-CELL (Beckman Coulter, Inc.). A total
of 5000 cells were grown in semisolid media consisting of 0.2% agar
noble (BD Biosciences) in triplicate for 3 weeks. Cells were stained
with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(Sigma-Aldrich) and were counted in triplicate.
Migration and Invasion Assays
Cells were counted on a Vi-CELL (Beckman Coulter, Inc.) and
plated in both uncoated and BD BioCoat growth factor–reduced
matrigel chambers (BD Biosciences) in quadruplicate for each cell
line. A total of 50,000 cells were placed in each chamber and incu-
bated for 48 hours. For the wild-type p53 and GFP control, adeno-
virus was added 24 hours before counting and plating. The chambers
were stained with 50 μl of 0.5% crystal violet in 20% methanol for
1 minute then swabbed on the inside to remove noninvasive cells,
washed twice in distilled water, and quantitated. Images of 14 fields,
representing 85% of the total surface area, were captured using a ×10
objective with a ×1.5 optivar on an Olympus IMT-2 microscope
(Olympus America Inc., Center Valley, PA), a Hamamatsu ORCA-
100 grayscale CCD camera (Hamamatsu USA, Bridgewater, NJ), and
a Ludl motorized XY stage (Ludl Electronic Products, Hawthorne,
NY). SimplePCI software version 6.2 (Compix, Inc., Sewickley,
PA) controlled the camera and stage, created a binary image, and
measured the image for the area. Significance was measured with
a one-sided Student’s t test comparing vector control and each mu-
tant treatment to the parental cell line.
Results
Generation of Human Mammary Epithelial
Model of Tumorigenesis
Four human mutant p53 cDNAs R175H, R273H, R280K, and
R249S were cloned, sequence-validated, and packaged as lentiviral
particles. These mutations represent the most common point muta-
tions of p53 in breast tissue. Stable HME1 cell lines expressing vector
only or cytomegalovirus promoter-driven mutant p53 were created
by lentiviral infection and blasticidin selection. The transduced mu-
tant p53 constructs were V5 epitope-tagged to discriminate between
exogenous mutant p53 and endogenous wild-type p53 protein in the
HME1 cells.
Stably Expressed Mutant p53 Causes Accumulation of the
Endogenous Wild-Type Protein
Western blot demonstrated that HME1 parental cells express low
but detectable levels of wild-type p53, and control viral infections did
not alter this level (Figure 1A). p53 levels in parental HME1 cells
increased with doxorubicin treatment, indicating that the endoge-
nous wild-type p53 response is functional (Figure 1A). In addition,
mutant p53 accumulated in the transduced HME1 cell lines (Fig-
ure 1, A and C, top bands). As expected, no proteins were detected
in the HME1, DOX, GFP, and Vector cell lines using the anti-V5
antibody (Figure 1B). The levels of exogenous V5-tagged mutant
p53 protein were variable in the HME1 cell lines (Figure 1B). The
R273H and R280K mutant protein levels were about 1.5 times higher
than the R175H and R249S. The endogenous wild-type p53 pro-
tein in the same cells was also accumulated (Figure 1, A and C,
bottom bands). Infection with a wild-type p53 adenovirus produced
accumulation of the protein to a similar level seen in the mutant
p53 stably infected HME1 cell lines (Figure 1C ). In the p53 hetero-
zygous HME1 cell lines, mutant p53 accumulates to similar levels as
the mutant protein in three breast cancer cell lines (Figure 1C ). Taken
together, the stable HME1 cell lines highly accumulate mutant p53 to
a level seen in breast cancer cell lines, and in response to the mutant
protein accumulation, the endogenous wild-type p53 accumulates to
a level that can be recapitulated by adenoviral infection of wild-type
p53 alone.
Exogenous Mutant and Endogenous Wild-Type p53
Protein Interact
We immunoprecipitated mutant p53 from cell lysates with an an-
tibody against the V5 tag to examine p53 interactions in the HME1
cells. The protein complexes were separated by SDS-PAGE and were
probed with p53 antibody. Mutant p53–infected cells revealed an in-
teraction between the exogenous mutant and endogenous wild-type
p53 proteins (Figure 2A). Quantification demonstrated equal amounts
of mutant and wild-type p53 protein in each immunocomplex, sug-
gesting that they bound in a stoichiometric manner (Figure 2B, com-
pare mut to w.t. for each mutant cell line).
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We examined subcellular localization of mutant and wild-type
p53. Results showed that mutant and wild-type p53 enter the
nucleus in each cell line tested (Figure 3). Taken together, these data
show the mutant p53 proteins are not defective either in tetrameriza-
tion or in nuclear trafficking.
Microarray Expression Analysis Supports the Dominant
Negative Activity of Mutant p53
We conducted microarray expression analyses to determine the ef-
fect of mutant p53 accumulation on gene expression in HME1 cells.
Because wild-type p53 was accumulated in the heterozygous mutant/
wild-type p53 HME1 cell lines, HME1 parental cells were also tran-
siently infected with wild-type p53 adenoviruses to produce a com-
parable level of p53 protein and induce a wild-type–only response
[33]. We then compared gene expression changes between wild-type
p53 only, and mutant/wild-type p53–expressing HME1 cells. Two
independent RNA samples from adenoviral wild-type p53 and the
four lentiviral mutant p53–infected cell lines were hybridized to
the GeneChip Human Genome U133A Plus 2.0 Array (Affymetrix).
Genes were selected as up or down regulated by filtering for genes
that showed a two-fold change in both of the duplicate hybridiza-
tions relative to the GFP only control for wild-type and vector only
control for mutant/wild-type p53–expressing cell lines. Entire gene
lists are available on request.
Induction of wild-type p53 from adenoviral infection of HME1
cells caused an increase in the expression of 599 genes (Table 1), in-
cluding known p53 targets such as p21, MDM2, WIG1, TP53I3,
TP53I5, TP73, TP53INP1, CSPG2, PIG11, PIG12, TP53TG1,
POLH, PCAF, MASPIN, and APAF1. Wild-type p53 also caused a
reduction in the expression of 748 genes (Table 1), such as FEN1,
PFS2, CSPG6, CDC2, MCM2, MCM6, MCM7, MSH2, and
MSH6, which has been previously demonstrated [34].
Although there is an equivalent level of wild-type p53 in adenoviral-
infected and mutant p53 lentiviral–infected HME1 cells (Figure 1C),
mutant p53 blocked changes in expression of the majority of wild-type
p53 target genes. Only a small fraction (3.6% to 6.7%) of the genes
affected by wild-type p53 was also targeted in the mutant/wild-type
p53 HME1 cell lines (Table 1). Real-time RT-PCR confirmed the
Figure 2. Endogenous wild-type p53 interacts with accumulated
exogenous mutant p53. Immunoprecipitations were conducted
with a non-specific antibody, or an anti-V5 antibody that recog-
nizes the exogenous mutant p53 protein. Western blots of the im-
munoprecipitates were conducted with an anti-p53 clone DO-1
antibody that recognizes both mutant and wild-type p53. (A) One
representative Western blot from three independently immuno-
precipitated samples. Lane 1 is 30 μg of whole cell lysate (WCL)
from HME1 as a positive control for p53. Even lanes 2 to 14 are
immunoprecipitates of the nonspecific antibody control. Odd
lanes 3 to 15 are V5 antibody–specific immunoprecipitates. (B)
Levels of wild-type p53 relative to the mutants in each HME1 mu-
tant p53–expressing cell line. The quantification and standard error
of the mean were calculated from Western blots of three indepen-
dent experiments and show the amounts of wild-type p53 (w.t.)
relative to the mutant p53 (mut) in each of the HME1 mutant
p53–expressing cell lines (R175H, R273H, R280K, and R249S).
Figure 1. Endogenous wild-type p53 accumulates in response to
mutant p53 accumulation. Western blots were conducted with ei-
ther anti-V5 or anti-p53 clone DO-1 and anti-actin as a loading con-
trol. (A) One representative Western blot from three independent
experiments shows p53 levels in parental (HME1), doxorubicin-
treated (DOX), GFP only control (GFP), vector only control (Vector),
and mutant p53–expressing HME1 cell lines (R175H, R273H,
R280K, and R249S). The double band for p53 in lanes 5 to 8 repre-
sents the exogenous V5-tagged mutant p53 as the larger protein
and the endogenous wild-type p53 as the smaller protein. (B) One
representative Western blot from three independent experiments
demonstrates the relative accumulation of the V5-tagged exoge-
nous mutant p53 in each of the mutant p53–expressing HME1 cell
lines; labels are the same as panel A. (C) One representative West-
ern blot from three independent experiments of adenoviral wild-
type p53 (Ad w.t. p53), mutant p53–expressing HME1 stable cell
lines (R175H, R273H, R280K, and R249S), MDA-MB-468, MDA-
MB-231, and BT549 breast cancer cell lines. The double band
for p53 in lanes 2 to 5 represents the exogenous V5-tagged mu-
tant p53 and the endogenous wild-type p53.
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microarray results for the induction of p21, MDM2, TP53I3, and
WIG1 by wild-type p53, and the ability of mutant p53 to block their
induction (Figure 4). The gene expression results demonstrated induc-
tion of wild-type p53 target genes in cells in response to wild-type p53
alone, but not in cells expressing wild-type and mutant p53. Thus,
these data confirm that mutant p53 induces a dominant negative effect
on wild-type p53 resulting in a lack of responsiveness of wild-type p53
target genes.
Chromatin Immunoprecipitation Analysis Confirms the
Dominant Negative Activity of Mutant p53
We used chromatin immunoprecipitation (ChIP) coupled to a
human promoter microarray to determine genome-wide DNA bind-
ing of p53 in our cell lines. DNA-protein complexes were immuno-
precipitated with p53 antibody, and then DNA was recovered,
fluorescently labeled, and hybridized to a 13,000-element human
promoter array. We found that 324 gene promoters were bound
by p53 after infection with wild-type p53 adenovirus (Figure 5A).
Of these, well-described p53 target genes PCNA, FAS, PLK3,
TP53INP1, CSPG2, PIG11, PIG12, TP53TG1, POLH, MASPIN,
and APAF1 were identified. The gene expression microarray analysis
for wild-type p53 confirmed that TP53INP1, CSPG2, PIG11,
PIG12, TP53TG1, POLH, MASPIN, and APAF1 promoter binding
resulted in increased expression.
Figure 3. Mutant p53 does not inhibit nuclear localization of wild-type p53 in HME1 cells. Parental (HME1), vector only control (Vector),
and mutant p53 (R175H, R273H, R280K, and R249S) stably expressing HME1 cells were assayed by immunofluorescence for subcellular
localization of p53. Cells were stained for p53 with Cy3 (top row, red). Nuclei were counterstained with 4′,6-diamidino-2-phenylindole
(middle row, blue). Images were merged to show nuclear localization of p53 in all cell lines (bottom row, pink).
Table 1. Wild-Type p53 Target Gene Changes in Mutant p53–Expressing Cells Compared to
Wild-Type p53 Response.
Wild-Type Changes Similarity to Wild-Type, n (%)
R175H R273H R280K R249S
Up 599 24 (4.0) 33 (5.5) 22 (3.7) 19 (3.2)
Down 748 46 (6.1) 67 (9.0) 26 (3.5) 29 (3.9)
Total 1347 70 (5.2) 90 (6.7) 48 (3.6) 48 (3.6)
The total number of gene changes in HME1 cells in response to wild-type p53 is represented on
the left. Similar gene changes in the mutant p53–expressing HME1 cells are presented under each
mutation. The percentage of the similar changes relative to wild-type p53 induction is presented in
parentheses. The bottom line shows the overall total of up and down gene changes.
Figure 4. Real-time RT-PCR confirms dominant negative activity of
mutant p53. The bar graphs represent average fold change in ex-
pression and standard error of the mean relative to parental HME1
cells for the vector only control, GFP control, wild-type adenoviral
p53 (Ad w.t. p53), and the mutant p53–expressing HME1 cell lines
(R175H, R273H, R280K, and R249S).
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ChIP coupled to real-time PCR confirmed the promoter microar-
ray analysis. The p53 protein was found binding to the promoters of
the identified genes APAF1, PLK3, FAS, and MASPIN in HME1
cells infected with wild-type p53 adenovirus (Figure 5B). GAPDH,
a non-p53 target gene, was used as a negative control, and the known
p53 target gene p21 was used as a positive control. These data dem-
onstrate that induced wild-type p53 resulted in specific DNA bind-
ing of wild-type p53 to the promoters of its target genes, and
confirms the specificity of p53 binding determined by the promoter
array hybridizations.
Each mutant p53 physically interacts with wild-type p53 and in-
hibits its binding to p53 target gene promoters (Figures 2A and 5A).
Overall, we saw a greater than 99% reduction of DNA binding in
HME1 cell lines expressing mutant and wild-type p53 (Figure 5A).
Therefore, mutant p53 protein accumulation is sufficient to block
specific wild-type p53-DNA interactions. These data explain and
complement the expression data, demonstrating a dominant negative
activity of mutant p53.
Microarray Expression Analysis Demonstrates Gain of
Function for Mutant p53
Although mutant p53 diminished the expression of wild-type p53
targets, each mutant p53 induced novel gene expression differences
(Figure 6A). The total number and direction of two-fold gene expres-
sion changes induced by each mutant p53 were variable (Figure 6A).
However, the trends of gene expression changes among the mutant
p53–expressing cell lines were very similar (Figure 6B). Each mutant
p53 caused an overlapping but unique spectrum of gene expression
changes compared to each other, as has been previously reported
[13,14]. STAU2 and E2F5 are two examples of genes upregulated
in all of the mutant p53–expressing cell lines, but not in wild-type
p53–induced cells. Real-time RT-PCR confirmed increases in the ex-
pression of these genes in response to mutant p53 accumulation (Fig-
ure 7). CDH11 and TFPI2 are two examples of genes downregulated
by mutant p53, and real-time RT-PCR verified their decreased ex-
pression (Figure 7). These changes are possibly indirect effects of mu-
tant p53 accumulation, because we did not detect p53 binding on
the promoter array for any genes in response to mutant p53. These
data demonstrate that even in the presence of wild-type p53, the mu-
tant protein can induce novel gene expression changes that support a
gain of function role for the mutant p53 proteins. Entire gene lists
are available on request.
Mutant p53 Does Not Induce Many Malignant Properties in
HME1 Cells
We conducted extensive analyses with the HME1 cells expressing
mutant p53 to test the acquisition of hallmark malignant phenotypes
in these cells. Flow cytometric analysis revealed that although there
was more wild-type p53 in the mutant p53–expressing cell lines they
were not susceptible to G1 arrest that is induced by wild-type p53
accumulation alone (Figure 8A). Additionally, in response to serum
deprivation, all cell lines arrested in G1 regardless of the expression of
mutant p53 (Figure 8B). Cell proliferation of HME1 cells was not
affected by accumulation of mutant p53, because each cell line tested
showed similar growth rates (Figure 8C ). A dilution series of the
HME1 cell lines also demonstrated no difference between the paren-
tal HME1 cells and cell lines with accumulated mutant p53 protein
(Figure 8D). Finally, none of the HME1 cell lines grew in semisolid
media, as opposed to MDA-MB-231 cells, which readily formed col-
onies (Figure 8E ). Taken together, the mutant p53 expressed in
HME1 cells did not increase cell proliferation, clonogenic potential,
anchorage-independent growth, or cell cycle distribution in an un-
treated or serum-deprived state. These results suggest that mutant
p53 when expressed with wild-type p53 in HMEC does not confer
many of the properties associated with malignant transformation.
Mutant p53 Increases Migration and the Invasive Potential
of hTERT-HME1 Cells
Although mutant p53 did not alter many phenotypes associated
with malignant transformation, it did change the migratory and in-
vasive potential of the HME1 cells. We conducted transwell assays to
determine the migratory and invasive potential of the parental and
vector control HME1 cells compared to the stably expressing mutant
Figure 5. Mutant p53 inhibits DNA binding of endogenous wild-
type p53. (A) Chromatin immunoprecipitation of p53 coupled to a
human gene promoter microarray was used to determine p53 bind-
ing throughout the genome. Data were analyzed from three inde-
pendent experiments plus dye swap. The bar graph represents
the number of elements bound by p53 in adenoviral wild-type p53–
infected HME1 cells (Ad w.t. p53) and the mutant p53–expressing
HME1 cells (R175H, R273H, R280K, and R249S) compared to the pa-
rental HME1 cells. Differentially bound promoters were determined
as explained in materials and methods. (B) Real-time PCR confirms
binding of adenoviral wild-type p53 to its target genes. The bar graph
represents the fold enrichment over input of the six genes in re-
sponse to adenoviral wild-type p53 infection. GAPDH is a control that
is not bound by p53, as evidenced by no enrichment of ChIP versus
input. The other genes confirm the ability of wild-type p53 to bind the
promoter regions of these genes in hTERT-HME1 cells after wild-
type p53 adenoviral infection.
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p53 HME1 cell lines. Cells expressing three of the four mutant p53
constructs, R273H, R280K, and R249S demonstrated increased mi-
gration (Figure 9A). On uncoated transwells, the R273H-, R280K-,
and R249S-expressing HME1 cells migrated three-, three-, and two-
fold, respectively, more than HME1 parental cells, P value < .03
(Figure 9B). On matrigel-coated transwells, the R273H-, R280K-,
and R249S-expressing HME1 cell lines demonstrated an eight-,
five-, and five-fold increase, respectively, in invasive potential com-
pared to the parental HME1 cells, which was statistically significant,
P value < .02 (Figure 9C ). The parental, vector control, and R175H
HME1 cell lines demonstrated minimal and insignificant differences
in migration and invasion (Figure 9, B and C ). The differences in
migration and invasive potential may be a result of the unique spec-
trum of gene expression differences caused by the different mutant
p53 proteins. Wild-type p53 caused a reduction in both migration
Figure 6. Mutant p53 alters patterns of gene expression in HME1
cells. Microarray expression analysis was conducted to determine
gene expression changes in response to mutant p53 accumula-
tion in HME1 cells. (A) The bar graph represents the number of
genes whose expression changed at least two-fold in response
to mutant p53–expressing HME1 cell lines (R175H, R273H,
R280K, and R249S). The top of each bar represents elements that
were increased in expression. The bottom of each bar represents
elements that were decreased in expression. The actual numbers
of increased and decreased elements are embedded in the
corresponding area of the graphs. (B) The heat map represents
the trends in gene expression in response to mutant p53. It shows
the expression levels in each mutant p53 cell line of every gene
that was found differentially expressed in at least one treatment
from panel A. Red and green indicate increases and decreases
in expression, respectively. Figure 7. Real-time RT-PCR confirms novel expression changes in-
duced by mutant p53. The bar graphs represent average fold
change in expression and standard error of the mean relative to
parental HME1 cells for the vector only control, GFP control, wild-
type adenoviral p53 (Ad w.t. p53), and the mutant p53–expressing
HME1 (R175H, R273H, R280K, and R249S) cell lines.
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and invasion compared to the parental and GFP adenovirally infected
control cells (Figure 9, A–C ). This reduction likely occurs because of
the cell cycle arrest and cell death induced by the accumulation of
wild-type p53 within the time frame of the assay.
Discussion
A multitude of previous studies have suggested a number of func-
tions for mutant p53 by expressing it in a variety of malignantly
transformed cells that were p53 null or wild-type. We have created
a unique model by stably infecting nonmalignantly transformed, im-
mortalized HMEC with mutant p53 to determine the role of p53
heterozygosity in tumorigenesis and malignancy acquisition. In this
model, accumulation of mutant p53 protein levels was similar to that
seen in three breast cancer cell lines. Interestingly, each mutant p53
in the cancer cell lines was slightly different in size, consistent with
differences found previously [8]. The mutant p53 consistently main-
tained the differences in size when expressed in the HME1 cell lines.
The change in size likely reflects differing posttranslational modifica-
tions that are unique to each mutant and occur when that protein is
expressed in any cell. Because we show that the mutant and wild-type
p53 proteins interact, the wild-type protein also likely receives the
same posttranslational modification as the mutant p53 protein.
Therefore, the wild-type p53 protein is consistently different in size
from the exogenous mutant by the size of the V5 tag, but among the
HME1 mutant p53–expressing cell lines, each mutant and wild-type
p53 protein are slightly different. Interestingly, the elevated levels of
mutant p53 protein were matched by a concomitant increase in the
endogenous wild-type p53.
We demonstrated that cellular p53 immunocomplexes were com-
posed of equal amounts of wild-type and mutant p53, consistent
with earlier studies [35]. We predict that the resultant accumulation
of endogenous wild-type p53 was likely due to the stabilization in-
duced by the interaction with the constitutively expressed exogenous
mutant protein. Additionally, we demonstrated by immunofluores-
cence that the mutant/wild-type p53 complexes were capable of en-
tering the nucleus. Thus, the missense mutation in the selected mutant
p53 proteins does not inhibit tetramerization or nuclear localization.
We compared genome-wide DNA binding and gene expression
profiles of the wild-type p53–induced and mutant p53–expressing
HME1 cell lines. We showed that induction of wild-type p53 alone
causes binding to a multitude of promoter regions in the genome
that are associated with expression changes of wild-type p53 target
genes. Mutant p53 inhibited the ability of wild-type p53 to bind
Figure 8.Mutant p53 has no effect on a variety of phenotypes associated with tumor cells. (A) One representative depiction of cell cycle
distribution demonstrates that the accumulation of different mutant p53 proteins has no effect on the cell cycle. Addition of wild-type
p53 induces a G1 arrest. (B) One representative depiction of cell cycle distribution following serum deprivation demonstrates G1 arrest
in all samples. Labels are the same from panel A. (C) The bar graph represents the average cell number and standard error of the mean
for each cell line at the indicated days. The y-axis is cell number × 100,000. (D) The bar graph represents the average number of colonies
and the standard error of the mean for each cell line at the indicated cell dilutions. (E) The bar graph represents the average and standard
error of the mean of colonies grown in semisolid media for each cell line. MDA-MB-231 cells were used as a positive control.
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the DNA of promoters of wild-type p53 target genes, and this inhi-
bition was recapitulated by changes in expression of only a small per-
centage of wild-type p53 target genes in the mutant/wild-type
heterozygous cell lines. Therefore, the mutant p53 protein is unable
to bind DNA and blocks the ability of wild-type p53 present in the
same cells from binding the response elements of target genes and
changing their level of expression. These results confirm the domi-
nant negative activity of mutant p53 and suggest that the accumulated
endogenous wild-type p53 is tolerated in the HME1 cells through the
inhibitory effects of the exogenous mutant p53.
Although the ChIP analysis demonstrated that DNA binding was
inhibited by mutant p53, each mutant p53 in the modeled hetero-
zygous state caused gene expression changes in the stably expressing
cell lines. It is possible that these gene changes reflect interference of
wild-type p53 by each mutant, but most of the genes that are changed
are not influenced by wild-type p53. Thus, the mutant p53 enacts
gene expression changes unique from inhibition of wild-type p53,
and without detectable DNA binding at the relevant control regions.
It is possible that the promoter array was not sensitive enough to detect
mutant p53 binding, but this is unlikely because it easily detected
binding by wild-type p53. An alternative hypothesis is that mutant
p53 enacts gene expression changes through an indirect interaction
with promoters by protein-protein interactions with other transcrip-
tion factors. Indeed, previous studies have demonstrated that mutant
p53 binds the transcription factors ETS, SP1, and NF-Y influencing
their activity [36–38]. The cross-linking used in this analysis was not
optimized to detect this type of protein-protein-DNA interaction.
These results confirm mutant p53 gain of function demonstrated pre-
viously in p53 null cancer cells and show that mutant p53 gain of
function can be demonstrated in a cellular background that contains
wild-type p53.
Interestingly, we demonstrated that mutant p53 accumulation in
HME1 had no effect on cell proliferation, clonogenicity, anchorage-
independent growth, or cell cycle distribution. Mutant p53 has been
shown to influence these malignant properties in other cell types and
models, but often the mutant p53 was expressed in previously trans-
formed cells in a p53 null background. Our data suggest that, at least
in nonmalignant HMEC expressing wild-type p53, the mutant p53
has no affect on these phenotypes. It may be that other defects com-
mon to malignant transformation are necessary to complement the
p53 mutation, the remaining wild-type p53 allele must be lost to gain
these additional phenotypes, or that the effects of p53 mutation are
tissue- and cell type–specific.
Although many malignant phenotypes were not acquired, we found
that introduction of mutant p53 increases the migratory and invasive
potential of human mammary epithelial cells harboring wild-type p53.
Interestingly, each mutant conferred differing levels of invasive poten-
tial from none (R175H) to high (R273H), possibly paralleling the
unique gene expression changes induced by each mutant. In each mu-
tant p53–expressing HME1 cell lines, the genes TFPI-2, TPM1, and
CLCA2 were downregulated. In pancreatic ductal adenocarcinomas,
the TFPI-2 gene is silenced by epigenetic inactivation, and reexpres-
sion of the gene in Panc1 cells reduces migration and invasion [39].
TPM1 gene expression was previously found reduced in MDA-MB-
231 cells in response to cytosine methylation, and reexpression of
the gene reduced migration in the MDA-MB-231 cells [40]. CLCA2
Figure 9. Mutant p53 accumulation causes an increase in migration and invasiveness of hTERT-HME1 cells. Migration assays using un-
coated inserts and invasion assays using matrigel-coated inserts were performed on the parental HME1 cell line (HME1), vector only con-
trol HME1 cell line (Vector), adenoviral GFP control (GFP), adenoviral infected wild-type p53 (Ad w.t. p53), and mutant p53–expressing
HME1 cell lines (R175H, R273H, R280K, and R249S). (A) Representative pictures of cells that migrated through the pores of the uncoated
inserts visualized by staining with crystal violet. (B) The bar graph represents the average fold difference of migration relative to the parental
HME1 cells through uncoated inserts. (C) The bar graph represents the average fold difference of invasion relative to the parental HME1
cells through matrigel-coated inserts. The cell lines were assayed in quadruplicate transwells for each experiment, and the averages were
graphed with the standard error of the mean. The asterisks indicate that R273H, R280K, and R249S showed a statistically significant in-
crease from the parental cell lines, P value < .05.
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expression is lost in malignant MDA-MB-231 and MDA-MB-468
cells, and reintroduction of this gene in MDA-MB-231 cells reduces
in vitro matrigel invasion and metastatic tumors in nude mice [41].
Because these genes were downregulated in all of the mutant p53–
expressing cell lines, they cannot fully explain the acquisition of mi-
gration and invasion, because all of the cell lines should have changed
and the R175H did not. It is interesting to note that the R175H cell
line had the most differences in expression compared to the other
mutant p53 cell lines (Figure 6B). It may be that other gene changes
induced a compensatory mechanism in the R175H cell line or that
other changes that are needed to become migratory and invasive were
absent in this cell line. Thus, each mutant p53 may have caused dif-
fering levels of migration and invasiveness because each caused a
unique spectrum of gene expression changes. Alternatively, mutant
p53 protein may interact with other proteins differently than its
wild-type counterpart causing changes in invasive potential. Previous
studies with p53 null human cancer cells exogenously expressing mu-
tant p53 have shown increased invasion and metastasis in mouse xeno-
graft models [17–19]. Recent studies demonstrated that R273H
mutant p53 can increase migration and invasion of wild-type p53–
expressing endometrial cancer HHUA cells [42]. Mouse mutant p53
knock-in models also suggest a role for mutant p53 in metastasis and
invasion [20,21]. These results taken with ours suggest that, even in
the presence of wild-type p53, certain p53 mutations can increase
cellular invasiveness.
In conclusion, we have developed a novel model system using
nonmalignant cells that is in agreement with the previously described
functional consequences of mutant p53 elucidated in malignant cells
and extends the increased invasiveness and metastatic potential of
p53 mutant/wild-type heterozygous status found in knock-in mouse
models to human mammary epithelial cells. Future studies will be
aimed at the elucidation of interactions of mutant p53 protein with
other protein partners and the mechanism of gene expression changes
induced by mutant p53. This model represents the earliest stages of
tumorigenesis and will be useful for determining how p53 mutation
drives the progression of noninvasive primary to metastatic breast
cancer in humans to create more effective treatment modalities to
block this important, early step in tumorigenesis.
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